Hypoxic tumor cell radiosensitization through nitric oxide

Nitric Oxide - Biology and Chemistry

Volumn 19, Issue 2, 2008, Pages 164-169

  De Ridder, Mark ^a   Verellen, Dirk ^a   Verovski, Valeri ^a   Storme, Guy ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Hypoxia; Macrophages; Nitric oxide; Nitric oxide synthase; Nuclear factor B; Radiosensitization

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; RADIOSENSITIZING AGENT;

DNA DAMAGE; HYPOXIA; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; RADIATION INJURY; RADIOSENSITIZATION; REVIEW; TUMOR CELL;

ANOXIA; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RADIATION TOLERANCE;

EID: 47249146419     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2008.04.015     Document Type: Review

References (66)

1. Howard-Flanders P., and Moore D. The time interval after pulsed irradiation within which injury to bacteria can be modified by dissolved oxygen. I. A search for an effect of oxygen 0.02 second after pulsed irradiation. Radiat. Res. 9 (1958) 422-437
2. Hall E.J. Radiobiology for the Radiologist (2000), Lippincott Williams & Wilkins
3. Thomlinson R.H., and Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9 (1955) 539-549
4. Brown J.M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol. 52 (1979) 650-656
5. Chaplin D.J., Olive P.L., and Durand R.E. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res. 47 (1987) 597-601
6. Vaupel P., Schlenger K., Knoop C., and Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 51 (1991) 3316-3322
7. Fyles A.W., Milosevic M., Wong R., Kavanagh M.C., Pintilie M., Sun A., Chapman W., Levin W., Manchul L., Keane T.J., and Hill R.P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48 (1998) 149-156
8. Stadler P., Becker A., Feldmann H.J., Hansgen G., Dunst J., Wurschmidt F., and Molls M. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 44 (1999) 749-754
9. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4 (2004) 437-447
10. Radiotherapy and hyperbaric oxygen. Report of a Medical Research Council Working Party. Lancet 2 (1978). 881-884.
11. Fein D.A., Lee W.R., Hanlon A.L., Ridge J.A., Langer C.J., Curran Jr. W.J., and Coia L.R. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J. Clin. Oncol. 13 (1995) 2077-2083
12. Overgaard J., Hansen H.S., Specht L., Overgaard M., Grau C., Andersen E., Bentzen J., Bastholt L., Hansen O., Johansen J., Andersen L., and Evensen J.F. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362 (2003) 933-940
13. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., Mose S., Beer K.T., Burger U., Dougherty C., and Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
14. Kaanders J.H., Pop L.A., Marres H.A., Bruaset I., van den Hoogen F.J., Merkx M.A., and van der Kogel A.J. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 52 (2002) 769-778
15. Adams G.E., and Cooke M.S. Electron-affinic sensitization. I. A structural basis for chemical radiosensitizers in bacteria. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 15 (1969) 457-471
16. Dische S. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother. Oncol. 3 (1985) 97-115
17. Denny W.A., and Wilson W.R. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert. Opin. Investig. Drugs 9 (2000) 2889-2901
18. Wink D.A., and Mitchell J.B. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic. Biol. Med. 25 (1998) 434-456
19. Howard-Flanders P. Effect of nitric oxide on the radiosensitivity of bacteria. Nature 180 (1957) 1191-1192
20. Mitchell J.B., Cook J.A., Krishna M.C., DeGraff W., Gamson J., Fisher J., Christodoulou D., and Wink D.A. Radiation sensitisation by nitric oxide releasing agents. Br. J. Cancer Suppl. 27 (1996) S181-S184
21. Mitchell J.B., Wink D.A., DeGraff W., Gamson J., Keefer L.K., and Krishna M.C. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res. 53 (1993) 5845-5848
22. Griffin R.J., Makepeace C.M., Hur W.J., and Song C.W. Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. Int. J. Radiat. Oncol. Biol. Phys. 36 (1996) 377-383
23. Verovski V.N., Van den Berge D.L., Soete G.A., Bols B.L., and Storme G.A. Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside. Br. J. Cancer 74 (1996) 1734-1742
24. Janssens M.Y., Verovski V.N., Van den Berge D.L., Monsaert C., and Storme G.A. Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation. Br. J. Cancer 79 (1999) 1085-1089
25. Janssens M.Y., Van den Berge D.L., Verovski V.N., Monsaert C., and Storme G.A. Activation of inducible nitric oxide synthase results in nitric oxide-mediated radiosensitization of hypoxic EMT-6 tumor cells. Cancer Res. 58 (1998) 5646-5648
26. Jordan B.F., Misson P., Demeure R., Baudelet C., Beghein N., and Gallez B. Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int. J. Radiat. Oncol. Biol. Phys. 48 (2000) 565-570
27. Jordan B.F., Gregoire V., Demeure R.J., Sonveaux P., Feron O., O'Hara J., Vanhulle V.P., Delzenne N., and Gallez B. Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res. 62 (2002) 3555-3561
28. Jordan B.F., Sonveaux P., Feron O., Gregoire V., Beghein N., and Gallez B. Nitric oxide-mediated increase in tumor blood flow and oxygenation of tumors implanted in muscles stimulated by electric pulses. Int. J. Radiat. Oncol. Biol. Phys. 55 (2003) 1066-1073
29. Xie Q.W., Whisnant R., and Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J. Exp. Med. 177 (1993) 1779-1784
30. Melillo G., Musso T., Sica A., Taylor L.S., Cox G.W., and Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 182 (1995) 1683-1693
31. Van den Berge D.L., De Ridder M., Verovski V.N., Janssens M.Y., Monsaert C., and Storme G.A. Chronic hypoxia modulates tumour cell radioresponse through cytokine-inducible nitric oxide synthase. Br. J. Cancer 84 (2001) 1122-1125
32. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310
33. Jung M., Zhang Y., Lee S., and Dritschilo A. Correction of radiation sensitivity in ataxia telangiectasia cells by a truncated IκB-α. Science 268 (1995) 1619-1621
34. Bradbury C.M., Markovina S., Wei S.J., Rene L.M., Zoberi I., Horikoshi N., and Gius D. Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-κB activation in HeLa cells occur via a mechanism involving p38 MAP kinase. Cancer Res. 61 (2001) 7689-7696
35. Russo S.M., Tepper J.E., Baldwin Jr. A.S., Liu R., Adams J., Elliott P., and Cusack Jr. J.C. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 50 (2001) 183-193
36. Wang C.Y., Mayo M.W., and Baldwin Jr. A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274 (1996) 784-787
37. De Ridder M., Van den Berge D.L., Verovski V.N., Monsaert C., Wauters N., and Storme G.A. NF-κB inhibition impairs the radioresponse of hypoxic EMT-6 tumour cells through downregulation of inducible nitric oxide synthase. Br. J. Cancer 88 (2003) 120-124
38. Raetz C.R., and Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71 (2002) 635-700
39. Engelhardt R., Mackensen A., and Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res. 51 (1991) 2524-2530
40. Jeannin J.F., Onier N., Lagadec P., von Jeney N., Stutz P., and Liehl E. Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat. Gastroenterology 101 (1991) 726-733
41. Onier N., Hilpert S., Reveneau S., Arnould L., Saint-Giorgio V., Exbrayat J.M., and Jeannin J.F. Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by lipid A in rats. Int. J. Cancer 81 (1999) 755-760
42. Onier N., Hilpert S., Arnould L., Saint-Giorgio V., Davies J.G., Jeannin J.F., and Jeannin J.F. Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats. Clin. Exp. Metastasis 17 (1999) 299-306
43. Reisser D., Pance A., and Jeannin J.F. Mechanisms of the antitumoral effect of lipid A. Bioessays 24 (2002) 284-289
44. Larmonier C.B., Arnould L., Larmonier N., Baumann S., Moutet M., Saint-Giorgio V., Pance A., and Jeannin J.F. Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer. Int. J. Mol. Med. 13 (2004) 355-361
45. Pance A., Reisser D., and Jeannin J.F. Antitumoral effects of lipid A: preclinical and clinical studies. J. Investig. Med. 50 (2002) 173-178
46. De Ridder M., Verovski V.N., Van den Berge D.L., Sermeus A.B., Monsaert C., Wauters N., and Storme G.A. Lipid a radiosensitizes hypoxic EMT-6 tumor cells: role of the NF-κB signaling pathway. Int. J. Radiat. Oncol. Biol. Phys. 57 (2003) 779-786
47. de Bono J.S., Dalgleish A.G., Carmichael J., Diffley J., Lofts F.J., Fyffe D., Ellard S., Gordon R.J., Brindley C.J., and Evans T.R. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin. Cancer Res. 6 (2000) 397-405
48. Bettaieb, A., Sassi, N., Gauthier, N., Chantôme, A., Reveneau S., Jeannin, J.F. Anti-tumor effect of lipid A-derived NO. First International Conference of NO and Cancer, Paris, 2008.
49. Xie Q.W., Kashiwabara Y., and Nathan C. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J. Biol. Chem. 269 (1994) 4705-4708
50. Bingle L., Brown N.J., and Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196 (2002) 254-265
51. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4 (2004) 71-78
52. Sersa G., Willingham V., and Milas L. Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int. J. Cancer 42 (1988) 129-134
53. Kimura K., Bowen C., Spiegel S., and Gelmann E.P. Tumor necrosis factor-α sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res. 59 (1999) 1606-1614
54. De Ridder M., Verovski V.N., Darville M.I., Van den Berge D.L., Monsaert C., Eizirik D.L., and Storme G.A. Macrophages enhance the radiosensitizing activity of lipid A: a novel role for immune cells in tumor cell radioresponse. Int. J. Radiat. Oncol. Biol. Phys. 60 (2004) 598-606
55. Cavaillon J.M. Cytokines and macrophages. Biomed. Pharmacother. 48 (1994) 445-453
56. Matsuura M., Saito S., Hirai Y., and Okamura H. A pathway through interferon-gamma is the main pathway for induction of nitric oxide upon stimulation with bacterial lipopolysaccharide in mouse peritoneal cells. Eur. J. Biochem. 270 (2003) 4016-4025
57. Thomsen L.L., Miles D.W., Happerfield L., Obrow L.G., Knowles R.G., and Moncada S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer 72 (1995) 41-44
58. Thomsen L.L., Lawton F.G., Knowles R.G., Beesley J.E., Riveros-Moreno V., and Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 54 (1994) 1352-1354
59. Ambs S., Merriam W.G., Bennett W.P., Felley-Bosco E., Ogunfusika M.O., Oser S.M., Klein S., Shields P.G., Billiar T.R., and Harris C.C. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 58 (1998) 334-341
60. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43 (1991) 109-142
61. Rosbe K.W., Prazma J., Petrusz P., Mims W., Ball S.S., and Weissler M.C. Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngoli. Head Neck Surg. 113 (1995) 541-549
62. Ambs S., Bennett W.P., Merriam W.G., Ogunfusika M.O., Oser S.M., Khan M.A., Jones R.T., and Harris C.C. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br. J. Cancer 78 (1998) 233-239
63. Klotz T., Bloch W., Volberg C., Engelmann U., and Addicks K. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 82 (1998) 1897-1903
64. Swana H.S., Smith S.D., Perrotta P.L., Saito N., Wheeler M.A., and Weiss R.M. Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J. Urol. 161 (1999) 630-634
65. Hajri A., Metzger E., Vallat F., Coffy S., Flatter E., Evrard S., Marescaux J., and Aprahamian M. Role of nitric oxide in pancreatic tumour growth: in vivo and in vitro studies. Br. J. Cancer 78 (1998) 841-849
66. De Ridder M., Verovski V.N., Chiavaroli C., Van den Berge D.L., Monsaert C., Law K., and Storme G.A. The radiosensitizing effect of immunoadjuvant om-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase. Int. J. Radiat. Oncol. Biol. Phys. 66 (2006) 1473-1480